---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000030"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:36:44.926094+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Novocure's Optune Lua for metastatic NSCLC after platinum progression

## Summary
- Optune Lua approved for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in patients with mNSCLC who progressed on/after platinum-based therapy.
- Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua + therapy) vs 9.9 months (control); 3.3-month gain (P=0.04).
- In PD-1/PD-L1 subgroup, median OS 19.0 months vs 10.8 months; 8.2-month gain (P=0.02).
- Device-related AEs in 63.1% of patients; mostly low-grade skin toxicity; no Grade 4/5 or deaths.
- First substantial OS improvement in >8 years for this patient population; wearable TTFields device.

## SEC filing metadata
- accession: 0001645113-24-000030
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000030/0001645113-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000030/nvcr-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000030
- JSON: https://secwatch.observer/filing/0001645113-24-000030.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.